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Abstract
Background: Epidural hematomas, cerebrospinal fluid fistula, and spinal infections 
are challenging postoperative complications following vertebro‑spinal procedures. 
We report our preliminary results using autologous fibrin sealant as both fibrin glue 
and a hemostatic during these operations.
Methods: Prospectively, between January 2013 and March 2015, 68 patients 
received an autologous fibrin sealant prepared with the Vivostat® system applied 
epidurally to provide hemostasis and to seal the dura. The surgical technique, time 
to bleeding control, and associated complications were recorded.
Results: Spinal procedures were performed in 68 patients utilizing autologous fibrin 
glue/Vivostat® to provide rapid hemostasis and/or to seal the dura. Only 2 patients 
developed postoperative dural fistulas while none exhibited hemorrhages, allergic 
reactions, systemic complications, or infections.
Conclusions: In this preliminary study, the application of autologous fibrin 
sealant with Vivostat® resulted in rapid hemostasis and/or acted as an effective 
dural sealant. Although this product appears to be safe and effective, further 
investigations are warranted.
Key Words: Autologous fibrin glue, cerebrospinal fluid fistula, dural repair, dural 
sealant, hemorrhage, hemostasis
INTRODUCTION
Cerebrospinal fluid (CSF) fistulas and postoperative 
hematomas constitute two of the major complications 
of spinal surgery.[2,13,21] Fibrin sealants supplement dural 
closure and promote hemostasis.[5,16,18] This study reports 
the preliminary results of utilizing a new fibrin sealant 
Vivostat® (Vivostat A/S, Alleroed, Denmark) to achieve 
both hemostasis and facilitate dural repair in spinal 
surgery.
MATERIALS AND METHODS
From January 2013 to March 2015, 68 patients undergoing 
spinal surgery received autologous fibrin sealant prepared 
with the Vivostat® system and applied epidurally, over the 
resection bed.
Patients population
Upon approval of the local Institutional Review Board, 
between January 2013 and March 2015 we performed 
68 neurosurgical spinal procedures utilizing autologous 
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fibrin sealant/Vivostat® to achieve hemostasis and/or to 
seal the dura.
In 47% of cases (32 cases), the autologous fibrin glue was 
used only as an hemostatic agent; in 34% of cases it was 
used both as an hemostatic and dural sealant agent for 
strengthening atretic dura (without frank CSF fistula); 
in 19% of cases the autologous fibrin glue was used to 
achieve both hemostasis and CSF fistula repair; [Table 1]. 
In the majority of cases, autologous fibrin glue addressed 
degenerative disease (43%) or tumor (oncological cases: 
32%) [Table 1, Figure 1]. For Vivostat preparation and 
administration see Graziano et al. and Giugno et al.[6‑8] 
All patients were monitored postoperatively for an average 
of 18 months.
RESULTS
Technical and economic considerations
This system was effective in all three circumstances; as 
a hemostatic alone, as a hemostatic and to strengthen 
atretic dura, and for hemostasis and dural repair. The 
Notably, Vivostat® formed an extremely thin white 
coat and did not compress the neural structures; 
additionally, it was physiologically eliminated within 
24–36 h [Figure 2]. Only in 2 cases postoperative CSF 
fistulas were encountered; 1 was successfully treated 
conservatively while the other required additional dural 
repair [Table 1]. Notably, no local medullar toxicity, 
allergic reactions, infection, or systemic complications 
Table 1: Patient data including the vertebro‑spinal procedures performed
Case 
number
Sex Age Pathology Treatment Dural opening Vivostat® 
indication
Postoperative 
complications
1 Male 50 Cervical disc herniation Microdiscectomy, arthroplasty No Hemostasis None
2 Male 67 Dorsal spondylodiscitis Decompression, arthrodesis No Hemostasis, dural 
sealing
None
3 Female 66 Dorsal meningioma Laminectomy and 
microsurgical asportation
Yes (intentional) Dural sealing None
4 Male 75 Dorsal pathologic fracture Arthrodesis No Hemostasis, dural 
sealing
None
5 Female 80 Lumbar canal stenosis Decompression, arthrodesis Yes (accidental) CSF fistula repair None
6 Female 60 Cervical myelopathy Decompression, arthrodesis Yes (accidental) CSF fistula repair None
7 Female 79 Cauda equina neurinoma Decompression, microsurgical 
asportation
Yes (intentional - 
duroplasty)
Dural sealing None
8 Female 76 Cervical myelopathy Decompression, arthrodesis No Hemostasis None
9 Female 69 Postoperative CSF fistula 
(lumbar canal stenosis)
CSF repair, duroplasty Yes (intentional) CSF fistula repair None
10 Female 77 Lumbar pathological fracture Decompression, arthrodesis No Hemostasis None
11 Male 57 Dorsal vertebral metastasis Decompression, arthrodesis No Hemostasis None
12 Female 53 Cervical extra-assial 
neoplasm
Decompression, microsurgical 
asportation, arthrodesis
No Hemostasis None
13 Male 54 Lumbar spondylolisthesis Decompression, arthrodesis Yes (accidental) CSF fistula repair Postoperative CSF 
fistula; conservative 
treatment
14 Male 51 Lumbar canal stenosis Arthrodesis system revision Yes (accidental) CSF fistula repair None
15 Male 52 Dorsal neoplasm Decompression, microsurgical 
asportation, arthrodesis
No Hemostasis None
16 Male 55 Dorsal extra-assial neoplasm Decompression, microsurgical 
asportation, arthrodesis
Yes (intentional - 
duroplasty)
Dural sealing None
17 Male 43 Lumbar CSF fistula CSf fistula repair Yes (intentional - 
duroplasty)
CSF fistula repair Postoperative CSF 
fistula; reintervention 
with other sealants
18 Female 72 Dorsal extra-assial neoplasm Decompression, microsurgical 
asportation
No Hemostasis None
19 Female 76 Dorsal epidural haematoma Decompression, evacuation Yes (accidental) Hemostasis CSF 
fistula repair
None
20 Female 53 Dorsal vertebral metastasis Decompression, arthrodesis No Hemostasis, dural 
sealing
None
21 Male 74 Lumbar canal stenosis Decompression, 
microdiscectomy, arthrodesis
Yes (accidental) Hemostasis CSF 
fistula repair
None
Contd...
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Table 1: Contd...
Case 
number
Sex Age Pathology Treatment Dural opening Vivostat® 
indication
Postoperative 
complications
22 Male 68 Dorsal vertebral metastasis Decompression, arthrodesis No Hemostasis None
23 Male 74 Lumbar pathologic fracture Decompression, arthrodesis No Hemostasis None
24 Male 65 Cervical canal stenosis Vertebral corpectomy Yes (accidental) Hemostasis, dural 
sealing
None
25 Male 55 Recidivant lumbar disc 
herniation
Decompression, 
microdiscectomy, arthrodesis
No Hemostasis None
26 Female 66 Lumbar spondylolisthesis Decompression, arthrodesis No Hemostasis None
27 Female 40 Dorsal vertebral metastasis Decompression, corpectomy No Hemostasis None
28 Male 39 Posttraumatic lumbar fracture Decompression, arthrodesis No Hemostasis None
29 Male 50 Recidivant lumbar disc 
herniation
Microsurgical discectomy, 
arthrodesis
No Hemostasis None
30 Male 50 Lumbar disc herniation Microsurgical discectomy, 
decompression, arthrodesis
No Hemostasis None
31 Male 77 Lumbar canal stenosis and 
spondylolisthesis
Decompression, arthrodesis No Hemostasis, dural 
strengthening
None
32 Male 55 Dorsal vertebral metastasis Decompression, arthrodesis No Hemostasis None
33 Male 61 Posttraumatic lumbar 
vertebral fracture
Decompression, arthrodesis Yes (accidental) CSF fistula repair None
34 Male 61 Posttraumatic lumbar 
vertebral fracture
Decompression, arthrodesis Yes (accidental) CSF fistula repair None
35 Male 66 Lumbar canal stenosis, 
recidivant lumbar disc 
herniation
Microdiscectomy, 
decompression, arthrodesis
Yes (accidental) Hemostasis CSF 
fistula repair
None
36 Male 67 Recidivant lumbar disc 
herniation
Microdiscectomy, 
decompression, arthrodesis
No Hemostasis None
37 Male 79 Cicatrizial adhesions in 
previous lumbar stenosis
Surgical decompression and 
adhesions resolution
No Hemostasis None
38 Female 57 Dorsal neurinoma Decompression, microsurgical 
asportation, arthrodesis
Yes (intentional) Hemostasis, dural 
sealing
None
39 Male 56 Lumbar canal stenosis Decompression, artrhodesis Yes (accidental) Hemostasis, dural 
sealing
None
40 Female 59 Dorsal vertebral burst fracture Laminectomy and arthrodesis No Hemostasis None
41 Female 68 Lumbar canal stenosis Decompression, arthrodesis Yes (accidental) Hemostasis, 
dural sealing, CSF 
fistula repair
None
42 Male 75 Epidural dorsal abscess Laminectomy, abscess 
drainage
No Hemostasis None
43 Male 77 Cervical canal stenosis Decompression, arthrodesis No Hemostasis None
44 Male 55 Lumbar canal stenosis Decompression, arthrodesis No Hemostasis None
45 Female 57 Lumbar extra-axial neoplasm Decompression, microsurgical 
asportation
Yes (intentional - 
duroplasty)
Hemostasis, dural 
sealing
None
46 Male 51 Cauda equina lipoma Decompression, microsurgical 
asportation
Yes (intentional - 
duroplasty)
Hemostasis, dural 
sealing
None
47 Male 66 Lumbar canal stenosis Decompression, arthrodesis No Hemostasis, dural 
strengthening
None
48 Female 56 Intramedullar dorsal 
metastasis
Decompression, microsurgical 
asportation
Yes (intentional - 
duroplasty)
Hemostasis, dural 
sealing
None
49 Female 87 Cervical tarumatic vertebral 
fracture
Arthrodesis No Hemostasis None
50 Female 84 Mielopathy (cervical trauma) Discectomy, corpectomy, 
arthrodesis
Yes (accidental) Hemostasis CSF 
fistula repair
None
51 Male 67 Dorsal traumatic vertebral 
fracture
Decompression, artodhesis No Hemostasis, dural 
strengthening
None
Contd...
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Table 1: Contd...
Case 
number
Sex Age Pathology Treatment Dural opening Vivostat® 
indication
Postoperative 
complications
52 Female 65 Lumbar tarumatic vertebral 
fracture
Arthrodesis No Hemostasis None
53 Male 60 Lumbar pathological fracture Decompression, 
thermo-ablation, artodhesis
No Hemostasis None
54 Male 71 Lumbar vertebral 
micro-instability
decompression, arthrodesis No Hemostasis None
55 Female 61 Lumbar canal stenosis, 
lumbar disc herniation
Decompression, 
microdiscectomy, arthrodesis
No Hemostasis, dural 
strengthening
None
56 Female 61 Lumbar canal stenosis, 
lumbar disc herniation
Decompression, 
microdiscectomy, arthrodesis
No Hemostasis, dural 
strengthening
None
57 Male 41 Cicatrizial adhesions and 
recidivant lumbar disc 
herniation
Decompression, adhesions 
resolution, microdiscectomy, 
arthrodesis
No Hemostasis None
58 Male 53 Intra-extradural lumbar 
vertebral metastasis
Decompression, microsurgical 
asportation, thermo-ablation, 
arthrodesis
Yes (intentional) Hemostasis, dural 
sealing
None
59 Female 54 Lumbar disc herniation, 
lumbar canal stenosis
Discectomy, arthrodesis No Hemostasis None
60 Female 60 Cervical burst fracture Corpectomy, arthrodesis Yes (accidental) Hemostasis, dural 
sealing
None
61 Male 54 Dorsal meningioma Decompression, microsurgical 
asportation
Yes (intentional - 
dural patch)
Dural sealing None
62 Male 67 Lumbar canal stenosis Decompression, arthrodesis No Hemostasis, dural 
strengthening
None
63 Female 48 Lumbar spondylolisthesis Arthrodesis No Hemostasis None
64 Male 72 Lumbar canal stenosis and 
spondylolisthesis
Decompression and 
arthrodesis
No Hemostasis, dural 
strengthening
None
65 Male 84 Cervical myelopathy and 
vertebral listhesis
Listhesis reduction and 
cervical arthrodesis
No Hemostasis None
66 Male 57 Dorsal vertebral metastasis Decompression, arthrodesis Yes (intentional) Hemostasis, dural 
sealing
None
67 Female 54 Dorsal vertebral abscess Decompression, biopsy No Hemostasis None
68 Male 52 Lumbar spondylodiscitis Decompression, 
microdiscectomy, arthrodesis
No Hemostasis None
CSF: Cerebrospinal fluid fistula
occurred. The cost per kit needed (e.g., automated 
preparation of 6.5 ml of fibrin glue) is around 700 USD. 
Each procedure typically requires only kit; only 5–10% of 
cases may require two kits.
DISCUSSION
Application for durotomies and hemostasis
In spinal surgery, the major intraoperative complications 
are typically due to accidental durotomies or postoperative 
hematomas. Cammisa et al. found 66 (3.1%) durotomies 
occurring during 2144 spinal operations; they were 
immediately treated with dural suturing and fibrin glue.[4] 
During minimally invasive spine surgery, the durotomy 
incidence has been estimated to be 9%, 4% among 
563 patients in the case series of Ruban and O’Toole.[17]
Figure 1: Graph showing the percentage of the pathologies included 
in the study
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Do dural sealants inhibit fusion
Some are concerned whether these sealants on the 
vertebral fusion rate.[5] Turgut et al. assessed the impact 
of Tisseel on anterior cervical interbody allograft fusion 
at the C5–C6 level in cats (12 received Tisseel, 12 did 
not); it was not suitable for “fixation of bone fragments” 
for anterior cervical discectomy and fusion in this cat 
model.[22] Landi et al. determined the efficacy of utilizing 
a topical platelet gel to supplement posterolateral fusions 
rates in 14 instrumented fusions; fusion rates were 
comparable for both groups at 6 postoperative months.[12]
Arguments favoring utilization of Vivostat system
The Vivostat® system is successfully used in several 
specialties.[1,3,10,11,14,15,19,20] The autologous nature of 
Vivostat® eliminates the risks of bovine or human‑borne 
contaminants, protecting the patient against viral diseases. 
It provides rapid polymerization, set rapidly, and provides 
instant tissue‑fibrin adhesion, enabling the surgeon to 
manipulate the treated area early.[9,23] In our clinical 
series, the Vivostat® provided immediate hemostasis 
without compression of neural tissues. Furthermore, there 
were 2 cases complicated by postoperative CSF fistula 
out of 68 patients treated, but only one required repeated 
surgical intervention.
CONCLUSION
Vivostat® system appears to be a safe/effective fully 
autologous hemostatic and dural sealant agent. Its 
composition and mechanism of action makes it able to 
adhere immediately to tissues and its rapid degradation 
time avoids any potential long‑term mass effect.
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